PsiOxus Therapeutics Revenue and Competitors

Claim your profile

Abingdon,

Location

$102.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • PsiOxus Therapeutics's estimated annual revenue is currently $18M per year.(i)
  • PsiOxus Therapeutics's estimated revenue per employee is $155,000
  • PsiOxus Therapeutics's total funding is $102.5M.

Employee Data

  • PsiOxus Therapeutics has 116 Employees.(i)
  • PsiOxus Therapeutics grew their employee count by 29% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$156.1M514-6%$145MN/A
#2
$14M90-37%$150MN/A
#3
$5.4M35-8%N/AN/A
#4
$4.8M31-22%N/AN/A
#5
$5.3M34-35%N/AN/A
#6
$53.9M348-35%$75.1MN/A
#7
$7.9M51-11%N/AN/A
#8
$14.7M95-4%N/AN/A
#9
$7910M158445%$204.3MN/A
#10
$13.2M106-49%$263.3MN/A

PsiOxus aims to be the world's leading cancer gene therapy company, delivering medicines of value to patients with cancer. We focus on discovering and developing innovative gene-based immuno-oncology treatments for solid tumors using our proprietary intravenously administered T-SIGn virus platform. Our portfolio of differentiated gene therapy products are all delivered systemically but act locally within the tumor. At PsiOxus we are advancing our internal early and clinical stage candidates and establishing strategic partnerships with immuno-oncology leaders to bring our cancer gene therapy products to patients. Find our more about us at www.psioxus.com

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$102.5M

Total Funding

116

Number of Employees

$18M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

PsiOxus Therapeutics News

2022-04-20 - Oncolytic Virus Therapy Market Size, Outlook And Forecast | Amgen ...

... Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics, Sorrento Therapeutics, Lokon Pharma.

2022-02-22 - PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb ...

PsiOxus aims to lead the world in tumor re-engineering, delivering medicines of significant benefit to patients with cancer. We focus on...

2022-02-22 - Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors

The study assessed the effect of giving bluebird's anti-EGFR CAR-T cells in combination with vectors in development at PsiOxus Therapeutics.

2019-09-08 - Oncolytic Virus Therapy Market Growth In Technological ...

... States),Oncolys BioPharma (Japan),BioVex (United States),Cell Genesys (United States),PsiOxus Therapeutics (United Kingdom),Shanghai ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.9M11810%N/A
#2
$31.6M1292%N/A
#3
$37.1M14113%$54.4M
#4
$28.1M14230%N/A
#5
$23.4M15123%N/A